semaglutide weight loss woodstock drug reduces risk of adverse cardiovascular events by 20% among overweight, obese patients No more confusion — the

Patent number: US10278961B2, CN108997332B, US20230138576A1

GLP-1 works in several important ways

Locatelli F, Fouque D, Heimburger O, Drueke TB, Cannata-Andia JB, Horl WH, et al

Scheduling: Both injected before bed

Why Retatrutide Could Redefine Obesity Treatment Retatrutide activates three metabolic pathways , giving it stronger appetite-suppressing and energy-regulating capabilities than existing drugs: Wegovy (semaglutide): GLP-1 mimetic Zepbound (tirzepatide): GLP-1 + GIP mimetic Retatrutide: GLP-1 + GIP + glucagon mimetic This triple-agonist profile may explain its superior results

One of its main effects is slowing down melanin production the pigment that causes dark spots and uneven skin tone